These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 29624804)

  • 1. Dialysis facility screening and testing practices in the era of improved hepatitis C treatment.
    Moore MS; Bocour A; Winters A
    J Viral Hepat; 2018 Sep; 25(9):1099-1101. PubMed ID: 29624804
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hepatitis C dissemination by hemodialysis: default isolation versus universal hygienic precautions (reply)].
    Mauro MM; Ficaccio C
    G Ital Nefrol; 2002; 19(1):82. PubMed ID: 12165951
    [No Abstract]   [Full Text] [Related]  

  • 3. Universal screening for hepatitis C: A needed approach in patients with haematologic malignancies.
    Angelidakis G; Hwang JP; Dandachi D; Economides MP; Hosry J; Granwehr BP; Torres HA
    J Viral Hepat; 2018 Sep; 25(9):1102-1104. PubMed ID: 29660201
    [No Abstract]   [Full Text] [Related]  

  • 4. Finding adolescents and young adults with transfusion-associated hepatitis C: looking forward to looking back.
    Jonas MM
    Arch Pediatr Adolesc Med; 2007 Feb; 161(2):202-3. PubMed ID: 17283308
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of electronic health record clinical decision support tool for HCV birth cohort screening.
    Fitch DN; Dharod A; Campos CL; Núñez M
    J Viral Hepat; 2017 Nov; 24(11):1076. PubMed ID: 28544048
    [No Abstract]   [Full Text] [Related]  

  • 6. [Hepatitis c virus infection in dialysis: necessity of prevention and screening].
    Poignet JL
    Nephrologie; 1997; 18(2):39-40. PubMed ID: 9182231
    [No Abstract]   [Full Text] [Related]  

  • 7. Half a diagnosis: gap in confirming infection among hepatitis C antibody-positive patients.
    McGibbon E; Bornschlegel K; Balter S
    Am J Med; 2013 Aug; 126(8):718-22. PubMed ID: 23786667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute hepatitis C.
    Marinos G; Post J
    Aust Fam Physician; 2003 Oct; 32(10):804-6. PubMed ID: 14596075
    [No Abstract]   [Full Text] [Related]  

  • 9. [Should pregnant women be tested for antibodies against hepatitis C virus?].
    Eskild A; Samdal HH
    Tidsskr Nor Laegeforen; 2000 Mar; 120(9):1067-9. PubMed ID: 10833968
    [No Abstract]   [Full Text] [Related]  

  • 10. Regarding 'Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective' by Loubière et al.
    Franklin IM
    Vox Sang; 2002 Jan; 82(1):50-1. PubMed ID: 11856469
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatitis C virus core antigen testing in the monitoring of patients on dialysis.
    Li Cavoli G; Zagarrigo C; Schillaci O; Tralongo A; Rotolo U
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):1056-8. PubMed ID: 22982924
    [No Abstract]   [Full Text] [Related]  

  • 12. Screening tests for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus in blood donors: evaluation of two chemiluminescent immunoassay systems.
    Sommese L; Sabia C; Paolillo R; Parente D; Capuano M; Iannone C; Cavalca F; Schiano C; Vasco M; De Pascale MR; Casamassimi A; Napoli C
    Scand J Infect Dis; 2014 Sep; 46(9):660-4. PubMed ID: 25073538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory diagnosis of Hepatitis C virus infection. A change to common practice.
    Hajeer AH; Memish ZA; Al-Knawy BA
    Saudi Med J; 2004 Jul; 25(7):827-9. PubMed ID: 15235682
    [No Abstract]   [Full Text] [Related]  

  • 14. Limited provision of diagnostic services to Victorians living with hepatitis C antibodies, 2001-2012: a multi-level modelling analysis.
    Snow K; Scott N; Clothier HJ; MacLachlan JH; Cowie B
    Aust N Z J Public Health; 2017 Apr; 41(2):193-198. PubMed ID: 27523715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions.
    Bruhn R; Lelie N; Busch M; Kleinman S;
    Transfusion; 2015 Jun; 55(6):1195-205. PubMed ID: 25727549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus in Cameroon.
    Fondjo CLK; Ngoupo PAT; Ngono L; Plantier JC; Njouom R
    BMC Res Notes; 2018 Jun; 11(1):352. PubMed ID: 29871688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eliminating hepatitis C.
    Burki T
    Lancet Infect Dis; 2019 Mar; 19(3):246-247. PubMed ID: 30833063
    [No Abstract]   [Full Text] [Related]  

  • 18. [Planning and significance of tests to confrim the presence of anti-hepatitis-C antibodies in blood donors. Spanish Study Group for Blood Donors at Risk].
    León P; Echevarría JM
    Sangre (Barc); 1999 Oct; 44(5):309-14. PubMed ID: 10618905
    [No Abstract]   [Full Text] [Related]  

  • 19. Converging epidemics: HIV and hepatitis C coinfection.
    Lusk H
    Focus; 2006 May; 21(5):1-5. PubMed ID: 16838423
    [No Abstract]   [Full Text] [Related]  

  • 20. [Immunoprophylaxis of viral hepatitis].
    Biesiada G; Mach T
    Przegl Lek; 2003; 60(9):598-601. PubMed ID: 15065341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.